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Abstract
Dysregulation of growth factor cell signaling is a major driver of most human cancers. This has led 
to development of numerous drugs targeting protein kinases, with demonstrated efficacy in the 
treatment of a wide spectrum of cancers. Despite their high initial response rates and survival 
benefits, the majority of patients eventually develop resistance to these targeted therapies. This 
review article discusses examples of established mechanisms of drug resistance to anticancer 
therapies, including drug target mutations or gene amplifications, emergence of alternate signaling 
pathways, and pharmacokinetic variation. This reveals a role for pharmacogenomic analysis to 
identify and monitor for resistance, with possible therapeutic strategies to combat 
chemoresistance.
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Introduction
Cancer is a genetic disease that arises primarily from the accumulation of genetic changes in 
genes regulating cellular growth, proliferation, and survival. Gain of function alterations 
inducing hyperactivity of oncogenes or loss of function alterations leading to inactivation of 
tumor suppressor genes cause deregulation of cellular signaling, a fundamental trait of 
cancer cells. In healthy cells, homeostasis is conveyed via growth factors binding to cell 
surface receptors, primarily protein kinases, which then activate intracellular signaling 
pathways and regulate cell cycle progression (Hanahan and Weinberg, 2011). Deregulation 
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of these signals results in uncontrollable cellular proliferation, metabolism, survival and, 
ultimately, cancer. Somatic (acquired, or tumor) mutations lead to constitutive activation of 
these signaling pathways. For example, mutations in the B-raf proto-oncogene, BRAF, a 
serine/threonine kinase, cause constitutive signaling through the mitogen-activated protein 
kinase (MAPK) pathway and are commonly observed in melanoma, colorectal (CRC), and 
papillary thyroid cancers (Araya et al., 2016). Identification of the genes and pathways 
deregulated in cancer, such as BRAF, has led to a rapid increase in the design and approval 
of therapies targeting these genetic drivers of oncogenesis. Targeted anti-cancer therapies 
function by interfering with specific molecular alterations that regulate cellular signaling and 
drive tumor growth. By binding to or inhibiting a known molecular driver, targeted therapies 
interrupt the signaling pathways, causing cellular deregulation and leading to cancer cell 
apoptosis or cell death. For example, vemurafenib selectively inhibits BRAF V600-mutated 
cancer cells, abrogating MAPK-mediated signaling, preventing proliferation of BRAF-
mutated cells, and ultimately resulting in apoptosis (Tsai et al., 2008).
To optimize the use of targeted therapies, the genetic alterations causing pathway 
deregulation in each patient’s tumor must be identified. This is the modern concept of 
personalized cancer medicine (or precision medicine). Pharmacogenomics is the study of 
how genetic variations influence the response of an individual to drugs. In the context of 
cancer, there are two genomes relevant to predicting drug response or resistance: (1) 
germline, or inherited, genetics may affect drug exposure, potentially causing variability in 
efficacy and/or toxicity, and (2) somatic, or tumor, genetics are the acquired alterations that 
may initiate and perpetuate cellular deregulation. Generally, it is the somatic germline that is 
interrogated to identify alterations driving oncogenesis and to select targeted therapies. It 
should be emphasized that drug resistance phenomena continue to be a primary hindrance to 
curative chemotherapy of solid tumors and hematologic malignancies (Fletcher et al., 2016; 
Niewerth et al., 2015; Wicki et al., 2016). Hence, deciphering the molecular mechanisms 
underlying chemoresistance should enhance targeted individualized cancer medicine 
(Assaraf et al., 2014; Livney and Assaraf, 2013; Swanton et al., 2016).
Due to their critical role in regulating cellular signaling, > 20 protein kinase inhibitors 
(PKIs) have been developed and approved across a wide range of tumor types. Despite their 
overall high response rates, many patients for whom the drugs are indicated will not have 
any evidence of disease control, while others will have transient benefit followed by tumor 
growth. This lack of complete and durable responses is indicative of drug resistance 
phenomena. If the correct alteration driving tumor growth is not identified from the outset, 
intrinsic resistance may be observed. When the tumor cells evolve to overcome targeted 
inhibition, the patient develops acquired resistance and stops responding to therapies that 
were previously effective. In this review, we will elaborate on the various classifications of 
cancer drug resistance, provide examples of how pharmacogenomics plays a role in 
resistance to PKIs, and discuss possible therapeutic strategies to overcome cancer drug 
resistance.
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Classifications of drug resistance mechanisms important in cancer
Drug resistance can be defined as the lack of therapeutic benefit or response to a medication. 
In the cancer setting, drug resistance is apparent with an increase in tumor size or metastasis 
(i.e. disease progression). Various mechanisms of chemoresistance can result in lack of 
complete or durable response to cancer therapies (Fig. 1). An overview of the common 
classifications is provided below. It is important to note that a single pharmacogenomic 
biomarker may represent multiple mechanisms of drug resistance.
Pharmacological vs. biological resistance
Pharmacological resistance reflects inadequate drug exposure at the drug target, and can be 
caused by environmental factors (e.g., drug-drug interactions, non-compliance), germline 
pharmacogenomics (i.e., inter-individual variability in drug metabolism or 
pharmacokinetics) (Fig. 1A & 1C) as well as drug sequestration away from its target (Goler-
Baron and Assaraf, 2011; Zhitomirsky and Assaraf, 2016). For example, addition of an 
antacid to alleviate gastroesophageal reflux caused by some PKI therapies will affect gastric 
absorption and exposure to the PKI, thereby leading to pharmacological resistance (Budha et 
al., 2012). Additionally, the observation that PKI-sensitive clones reemerge post-PKI 
discontinuation demonstrates the cytostatic, rather than cytotoxic, nature of some targeted 
therapies (Browning et al., 2013; Sequist et al., 2011). Therefore, inconsistent suppression of 
the drug target due to missed doses may lead to upregulation of the cancer-driving pathways 
and, ultimately, cancer progression. Biological resistance results from cancer cell evolution 
in the presence of adequate drug exposure (Fletcher et al., 2016; Liu et al., 2016; Niewerth et 
al., 2015). In the context of cancer, biological resistance can arise from somatic alterations in 
drug targets or pathways (Fig. 1B & 1C). Examples include genetic alterations in the drug 
target itself, activation of alternative signaling pathways (bypass tracks), alteration in 
signaling proteins downstream of the drug target, or phenotypic switch. Most known 
mechanisms of resistance to targeted cancer therapies are of the biological resistance 
subtype; hence, these will be the primary focus of this article.
Intrinsic vs. acquired resistance
Cancer drug resistance can also be classified based on timing during the course of treatment. 
Intrinsic resistance (also referred to as innate, inherent, or primary resistance) is the absence 
of discernible, even transitory beneficial effect from a medication. From the outset, there is 
neither cessation in tumor growth nor increase in survival benefits (Fig. 1D). Evidence of 
intrinsic resistance can be visualized in a waterfall plot, in which some patients fail to ever 
meet Response Evaluation Criteria in Solid Tumors (RECIST). For example, approximately 
20% of BRAF V600-mutated melanoma patients do not respond to BRAF inhibitors 
(Hauschild et al., 2012), demonstrating intrinsic drug resistance. Mechanisms of intrinsic 
resistance can include germline or somatic alterations. Intrinsic resistance is a major 
challenge in cancer therapy, and it is important to elucidate the mechanisms conferring lack 
of therapeutic benefit. However, these mechanisms remain less well understood at this time.
Acquired or secondary resistance is the progression of disease after an initial benefit. In 
oncology, the tumor initially shrinks (responds) but eventually begins to increase in size 
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(Fig. 1E). While intrinsic drug resistance can be due to germline or somatic mutations, 
acquired resistance is most commonly attributed to somatic mutations (an exception would 
be a new drug-drug interaction due to changes in therapy). Mechanisms that result in 
acquired drug resistance include genetic alterations in the drug target, activation of bypass 
tracks, alteration in downstream signaling proteins, phenotypic switch, drug efflux, drug 
catabolism as well as drug compartmentalization (Camidge et al., 2014; Gridelli et al., 2014; 
Liu et al., 2016).
Germline pharmacogenomics as a mechanism of pharmacological 
resistance
Germline pharmacogenomics can affect one’s inherent response to a medication or therapy. 
In the context of cancer, germline pharmacogenomics has most widely been associated with 
risk of developing adverse effects, rather than drug resistance (Hertz and Rae, 2015). Since 
adverse effects generally result from off-target (i.e., non-tumor) effects, it is logical that 
genetic variation in the germ cells throughout the body would confer risk to adverse events. 
However, due to the inherited nature of germline genetics, they may also play a role in one’s 
initial response to therapy. In fact, there are a few well-studied examples of how germline 
variation can confer intrinsic resistance to anticancer medications (Table 1).
Germline variation in TPMT as a pharmacogenomics predictor of response and adverse 
events
Germline variation in TPMT, the gene that encodes the thiopurine S-methyltransferase 
(TPMT) enzyme, is known to affect response to thiopurine drugs. Chemotherapeutic 
thiopurines include 6-mercaptopurine and 6-thioguanine, which are used in the treatment of 
pediatric and adult acute lymphocytic leukemia (ALL) (azathioprine is a prodrug of 6-
mercaptopurine used in non-malignant conditions). Thiopurine drugs are inactive prodrugs 
that are bioactivated and metabolized via competing routes: (1) xanthine oxidase converts 6-
mercaptopurine to an inactive metabolite, 6-thiouric acid; (2) hypoxanthine 
phosphoribosyltransferase (HPRT) converts thiopurines to activated nucleotide analogues, 
which can be incorporated into DNA or RNA, hence interfering with replication and 
transcription, resulting in cytotoxicity; and (3) TPMT inactivates thiopurines through 
methylation. The nucleotide analogues formed by HPRT are responsible for the efficacy and 
toxicity of thiopurine drugs, and insufficient TPMT activity results in upregulation of HPRT-
mediated metabolism, conferring response. Patients with low TPMT activity have greater 
exposure to activated thioguanine nucleotides, resulting in the potential for greater efficacy, 
but also increased risk of severe toxicity (Lennard et al., 1997). This variation in activated 
nucleotide exposure is well-established as a predictor of treatment outcomes. Patients with 
TPMT loss-of-function variants have significantly lower rates of minimal residual disease 
positivity after receiving 6-mercaptopurine therapy when compared to wild type TPMT 
individuals (Stanulla et al., 2005). Increased risk of relapse has also been associated with 
wild type TPMT in children receiving 6-mercaptopurine, likely due to insufficient 
thioguanine nucleotide exposure, thus conferring a type of pharmacological resistance 
(Schmiegelow et al., 2009). Due to increased toxicity risk, decreased dosing for patients 
with TPMT variants has been recommended (Relling et al., 2011). However, it is unclear 
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how this may affect relapse rates (Levinsen et al., 2014; Relling et al., 2006). A recent study 
reported that patients with 6-mercaptopurine non-adherence were at a 2.7-fold increased risk 
of relapse when compared to patients with a mean drug adherence rate of 95% or greater (p 
= 0.01), further emphasizing the importance of continuous drug exposure and adherence as a 
means to avoid development of drug resistance phenomena (Bhatia et al., 2015).
Germline alterations in BIM as a predictor of intrinsic pharmacological resistance
A common variant in BCL2L11 (also known as BIM), the gene that encodes the BCL2-like 
11 protein, has been associated with intrinsic resistance to PKIs. BIM is a member of the B-
cell CLL/lymphoma 2 (Bcl-2) family of genes and encodes a Bcl-2 homology domain 3 
(BH3). BH3 activates cell death by either opposing the pro-survival members of the Bcl-2 
family or by binding to the pro-apoptotic Bcl-2 family members and causing activation of 
their pro-apoptotic functions (Youle and Strasser, 2008). PKIs induce upregulation and 
stabilization of BIM through inhibition of the MAPK pathway, therefore, the activity of BIM 
is required for PKIs to induce apoptosis in kinase-driven cancers (Gong et al., 2007). 
Recently, a 2,903 bp germline deletion polymorphism in intron 2 of BIM was identified, 
which was associated with inferior responses to PKIs (i.e., imatinib, gefitinib, erlotinib, and 
afatinib) in chronic myeloid leukemia (CML), non-small cell lung cancer (NSCLC), and 
pediatric ALL patients (Lee et al., 2014; Ng et al., 2012; Soh et al., 2014). Functionally, this 
mutation results in alternative RNA splicing, leading to decreased production of BIM 
isoforms containing the essential BH3 domain.
Since its discovery, conflicting evidence of the ability of BIM variation to predict intrinsic 
resistance to PKIs has been documented (Chen et al., 2014; Cheng and Sawyers, 2012; Isobe 
et al., 2014). Two retrospective studies failed to observe an association between BIM 
genotype and response rates to PKIs in NSCLC patients (Lee et al., 2013; Lee et al., 2015a). 
However, a systematic review and meta-analysis of 951 patients supported the BIM deletion 
polymorphism as a predictor of shorter progression free survival (PFS) in NSCLC patients 
who were treated with PKIs (adjusted HR = 2.38, p < 0.001) (Nie et al., 2015). Another 
meta-analysis found that the BIM deletion polymorphism was associated with response rates 
(HR = 0.44, 95% CI = 0.27–0.7) and PFS (HR = 2.19, 95% CI = 1.7–2.8) in NSCLC, but not 
in CML (Ying et al., 2015). Further evidence indicating a lack of benefit or increased risk of 
harm in individuals carrying BIM deletions must be generated before this biomarker of 
intrinsic resistance can reasonably be implemented in clinical practice.
Methods to overcome BIM-related PKI resistance are already being explored. A preclinical 
study in NSCLC cell lines and xenograft models indicated that cells harboring the common 
BIM deletion had enhanced response to gefitinib when treated in combination with a histone 
deacetylase inhibitor, vorinostat (Nakagawa et al., 2013). Vorinostat functioned by 
increasing expression of BH3 in a dose-dependent manner, thus restoring sensitivity to 
tyrosine kinase inhibition. These findings further support the importance of BIM expression 
in PKI response and provide evidence to suggest that combination therapeutics may be a 
potential strategy to overcome this form of resistance.
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Additional germline pharmacogenomic markers as predictors of drug resistance
One potential mechanism that can confer pharmacological resistance is decreased exposure 
at the drug target, which can result from drug-drug interactions or inter-individual genetic 
variability (Fig. 1A). There are a few well-established examples of germline genetics 
affecting exposure to anticancer therapies [reviewed in (Hertz and Rae, 2015)]. While 
outside the scope of this review, the importance of an established link between active drug 
exposure levels and clinical outcomes or adverse events must be noted. Drug exposure is 
predicted to affect drug efficacy or toxicity. However, discrete evidence must exist before 
clinical implementation is warranted (Gillis and Innocenti, 2014).
Somatic pharmacogenomics as a mechanism of drug resistance
Somatic mutations result in upregulation of oncogenic pathways, and their effects can be 
inhibited with the use of targeted therapies. Since 2003, over 20 PKIs have been approved to 
target various somatic alterations across a broad range of cancer types (including 
hematologic and solid malignancies), and more than 20 additional PKIs are currently in 
clinical trials (CenterWatch, 2016). Because these drugs target protein kinases, somatic 
alterations in the targets or pathways may confer resistance or response (Table 1). Some 
well-established examples of somatic genetic drivers of resistance to PKIs are discussed 
below.
RAS status as a predictor of intrinsic resistance to EGFR inhibition in CRC
The epidermal growth factor receptor (EGFR or ErbB-1) is a transmembrane protein kinase 
that binds epidermal growth factor, inducing dimerization and autophosporylation, which 
signals downstream pathways (i.e., MAPK and PI3K/Akt) that mediate cellular proliferation 
and survival (Fig.2). The EGFR signaling pathway plays a pivotal role in tumor growth and 
progression in many cancer types, including glioblastoma, NSCLC, head and neck cancers, 
and CRC. EGFR is overexpressed in approximately 50% of CRC patients, and is associated 
with disease progression and poor prognosis (Siena et al., 2009). Anti-EGFR monoclonal 
antibodies, such as cetuximab and panitumumab, were hypothesized to be effective in 
colorectal tumors over-expressing EGFR, and were initially U.S. Food and Drug 
Administration (FDA) approved for that indication. However, as monotherapy, the response 
rates to cetuximab and panitumumab were only 10% and 30%, respectively, indicating 
potential intrinsic resistance (Jonker et al., 2007; Van Cutsem et al., 2007). Retrospective 
analysis of phase III clinical study data revealed differential response to anti-EGFR 
monoclonal antibodies dependent on Kirsten rat sarcoma viral oncogene (KRAS) homolog 
(Amado et al., 2008). When stratified by KRAS mutation status, response rate to 
panitumumab in wild type individuals was 17%, whereas 0% of individuals with mutant 
KRAS responded. Similarly, KRAS mutations were associated with resistance and 
decreased overall survival (OS) in patients receiving cetuximab (Lievre et al., 2006). These 
observations provided evidence for KRAS as a biomarker of intrinsic resistance to EGFR-
targeted monoclonal antibodies.
KRAS is a member of the rat sarcoma virus (RAS) family of oncogenes, which also includes 
HRAS (Harvey rat sarcoma viral oncogene homolog) and NRAS (neuroblastoma RAS viral 
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oncogene homolog). Mutations in RAS genes lead to the constitutive activation of the 
MAPK pathway independent of EGFR status. Interestingly, in CRC, mutations in KRAS are 
significant enough to negate EGFR inhibition. A prospective-retrospective analysis of 1,183 
patients who received either FOLFOX-panitumumab or FOLFOX alone revealed that 
mutation status in both KRAS and NRAS were predictive of response to panitumumab (HR 
for progression or death in RAS wild type 0.72, 95% CI 0.58–0.99, p= 0.0004) (Douillard et 
al., 2013). Recently, the American Society of Clinical Oncology released a provisional 
clinical opinion update recommending NRAS and KRAS mutation testing in CRC patients 
who are candidates for anti-EGFR monoclonal antibodies, supporting the significance of this 
biomarker as a predictor of intrinsic drug resistance (Allegra et al., 2016). Additional 
potential markers of intrinsic resistance have since been identified in models of KRAS wild-
type patient xenografts, including ERBB2 (HER2), FGFR1, PDGFRA, and MAP2K1 
(MEK); secondary mutations in EGFR at the site of cetuximab binding were identified in 
acquired resistance (Bertotti et al., 2015). Further studies demonstrating effects on patient 
outcomes are needed before clinical implementation of these novel biomarkers can be 
recommended.
EGFR status as a mediator of resistance to EGFR PKIs in NSCLC
Mutations in EGFR are one of the most common cancer drivers identified in NSCLC 
tumors. Approximately 15% of NSCLC patients in the U.S. will have an EGFR mutation, 
and the incidence is approximately 35% in patients of Asian descent (Shi et al., 2014b). In 
the U.S., EGFR mutations are most prevalent in females (17.9% vs. 8%, p= 0.002), non-
smokers (42% vs. 6.6%, p < 0.001), and adenocarcinomas (15.6%) (Bauml et al., 2013). The 
mutations are typically located in exons 18 to 21 of EGFR, the region that encodes the 
catalytic tyrosine kinase domain. Approximately 90% of the mutations are short exon 19 
deletions or the L858R point mutation in exon 21, which result in enhanced EGFR signaling 
(Sharma et al., 2007). Mutations in EGFR are predictive of response to EGFR inhibitors, 
such as erlotinib and gefitinib, in NSCLC. However, despite 70–80% response rates to 
EGFR PKIs, a majority of patients will acquire resistance after 10–12 months (Mitsudomi et 
al., 2010; Zhou et al., 2011). Additionally, absence of initial EGFR mutations confers lower 
overall response rates in NSCLC patients, a relative intrinsic resistance (Morgensztern et al., 
2015; Yang et al., 2015).
Acquired resistance to EGFR inhibitors in NSCLC is complex and heterogeneous, but 
ultimately all mechanisms drive sustained signaling through downstream cancer pathways 
(e.g., MAPK or PI3K/Akt pathways). Known mechanisms of drug resistance include 
secondary genetic alterations in EGFR, upregulation of parallel signaling pathways, or 
phenotypic transformation (Fig. 2). The most common mechanism of acquired resistance in 
EGFR-positive NSCLCs is the single-nucleotide mutation T790M, which occurs in 
approximately 50–60% of acquired resistance cases (Sharma et al., 2007). Also known as 
the gatekeeper residue, substitution of bulky methionine at this position causes steric 
hindrance and prevents EGFR inhibitors from binding and eliciting their pharmacologic 
effect. Other EGFR mutations have been identified in patients with acquired resistance, but 
their frequencies are much lower (Fig. 3). Another common mechanism of acquired 
resistance to EGFR PKIs is amplification of the MET proto-oncogene (MET), a receptor 
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tyrosine kinase, which has been reported in up to 22% of resistant samples (Engelman et al., 
2007). MET amplification drives resistance by inducing EGFR-independent phosphorylation 
of ERBB3 (HER3), which activates downstream PI3K/Akt signaling despite the presence of 
an EGFR inhibitor (Engelman et al., 2007). Amplifications of ERBB2 (HER2) and PIK3CA 
have also been identified in patients with acquired resistance, similarly functioning to 
activate shared pathways independent of EGFR (Sequist et al., 2011; Yu et al., 2013). 
Phenotypic transformation as a mechanism of acquired resistance occurs when the histology 
of the tumor transitions to small cell lung cancer (SCLC) or from epithelial to mesenchymal 
(EMT) subtype, and occurs in approximately 14% and 5%, respectively (Sequist et al., 2011; 
Takegawa et al., 2016). Interestingly, transformed SCLCs retain the primary EGFR 
activating mutations, but do not carry T790M or MET amplification. Not much is known 
about the mechanism of histological transformation, but currently it is recommended that 
these patients receive standard SCLC treatments (Oser et al., 2015).
Numerous strategies are being investigated to overcome first generation EGFR inhibitor 
resistance due to secondary EGFR mutations or bypass track signaling. One strategy was to 
develop more potent inhibitors of EGFR. The FDA-approved second-generation EGFR 
inhibitor, afatinib, which irreversibly binds to and inhibits EGFR as well as HER2, HER3, 
and HER4. Despite its first-line indication and increased potency, afatinib has not 
demonstrated promise in the setting of acquired drug resistance. LUX-Lung 1, a phase 2b/3 
trial of afatinib in patients who had progressed after treatment with an EGFR PKI, failed to 
meet its primary endpoint of OS (HR 1.08, 95% CI 0.86–1·35; p=0.74), and response rates 
were less than 10% (Miller et al., 2012). Demonstrating more promise than the second 
generation EGFR PKIs in combating acquired resistance are the third generation EGFR 
inhibitors: the recently approved osimertinib as well as rociletinib that is in clinical trials. 
Like the second-generation inhibitors, these are irreversible EGFR inhibitors. However, they 
have higher affinity for mutant EGFR, including T790M, than for wild type EGFR. In the 
pivotal phase 2 study of osimertinib in NSCLC patients who had progressed after treatment 
with a first generation PKI, response rates in T790M-positive patients were 61%. In a 
similar phase 1/2 study of rociletinib, patients with the T790M mutation had an objective 
response rate of 59% (Janne et al., 2015; Sequist et al., 2015).
Despite their therapeutic promise in acquired resistance to first generation EGFR PKIs, 
mechanisms of potential acquired resistance to third generation EGFR PKIs have already 
been reported. A study in patients who progressed on rociletinib reported that half of 
T790M-positive NCSLCs treated with rociletinib became T790-wild type at progression 
(Piotrowska et al., 2015). Loss of T790M was also observed in 27% patients who progressed 
on osimertinib, and 40% acquired a novel EGFR mutation, C797S, which is also resistant to 
rociletinib (Thress et al., 2015). A strategy that is being tested to overcome loss of T790M is 
combination therapy of an EGFR PKI with a monoclonal antibody that targets EGFR (e.g., 
NCT02496663). Recently, a preclinical study identified mutations and amplifications in 
NRAS and KRAS as mechanisms of acquired resistance to osimertinib (Eberlein et al., 
2015). Due to their upstream signaling of MEK, alterations in NRAS and KRAS may confer 
response to MEK inhibitors. As such, clinical studies investigating combination therapy with 
third generation EGFR PKIs and MEK inhibitors are also underway (e.g., NCT02580708).
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Therapeutic strategies targeting resistance mediated by upregulation of bypass signaling 
pathways are less established. Postulated strategies mainly consist of studies investigating 
dual inhibition of EGFR and known bypass tracks. In an ongoing phase 1b/2 clinical study 
of gefitinib plus a novel MET inhibitor (INC280) in patients who had progressed on a first-
line EGFR PKI, partial responses were only observed in 6/41 (15%) individuals (Wu et al., 
2014). A phase 1b study investigated concurrent inhibition of HER2 and EGFR with the 
combination of afatinib (dual HER2/EGFR inhibitor) and cetuximab in NSCLC patients 
who had progressed on gefitinib or erlotinib, and overall response rate (ORR) was 29%, and 
PFS was 4.7 months (Janjigian et al., 2014). A phase 2 clinical trial combining erlotinib with 
a PI3K inhibitor (BKM120) is currently ongoing in patients who acquired resistance to 
erlotinib (NCT01487265); the combination of afatinib and sirolimus is also being studied to 
overcome resistance due to mTOR (mechanistic target of rapamycin, a serine/threonine 
kinase) activation (NCT00993499), a downstream component of the PI3K/Akt pathway. 
These preliminary results suggest that dual inhibition of multiple signaling pathways may 
confer response in some individuals. However, an understanding of which individuals will 
benefit and durability of response is crucial.
Acquired resistance to ALK inhibitors
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is normally expressed 
in the nervous system and plays an important role in brain development. ALK 
rearrangements, mutations, and amplifications have been identified in numerous tumor types 
including anaplastic large cell lymphoma, neuroblastoma, and NSCLC. Chromosomal 
rearrangements resulting in gene fusions are the most common type of ALK alterations. 
Clinically, ALK alterations are known to be most actionable in NSCLC, where the most 
common rearrangement observed is echinoderm microtubule associated protein like 4 
(EML4)-ALK (Soda et al., 2007). Multiple variants of EML4-ALK have been reported; 
however, they all encode the same cytoplasmic portion of ALK, but have different EML4 
truncations (Choi et al., 2008). Fusions of ALK with other genes have also been described 
(e.g., KIF5B-ALK, TFG-ALK, and KLC1-ALK), but occur at much lower frequencies 
(Shaw and Engelman, 2013). These fusion proteins mediate ligand-independent dimerization 
of ALK, and like EGFR mutations, result in constitutive activation and downstream 
signaling through the MAPK and PI3K/Akt pathways (Soda et al., 2007). Interestingly, ALK 
gene arrangements are largely mutually exclusive with EGFR or KRAS mutations (Gainor et 
al., 2013). Cancers harboring ALK rearrangements, classified as ALK positive, derive 
clinical benefit from ALK PKI therapies.
Crizotinib is a first generation ALK PKI, which also inhibits the MET and ROS proto-
oncogenes (MET and ROS1), which encode receptor tyrosine kinases. Crizotinib first 
received accelerated FDA approval for ALK-positive NSCLC in 2011 based on durable, 
objective response rates of 61% in a single-arm phase 1 study, and is now recommended 
first-line in ALK-rearranged NSCLC (Camidge et al., 2012). Crizotinib inhibits ALK 
phosphorylation and signal transduction through G1-S phase cell cycle arrest and induction 
of cellular apoptosis (Christensen et al., 2007). Despite high response rates (74% in the first-
line phase 3 study), resistance to crizotinib develops 10–12 months after therapy initiation 
(Solomon et al., 2014).
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As observed with EGFR inhibitors, acquired resistance to crizotinib is heterogeneous and 
complex (Fig. 3). Mechanisms of resistance that have been reported include somatic 
alterations (amplification and/or mutation) in ALK, activation of alternative signaling 
pathways, and genetic alterations in other important oncogenes. A case of phenotypic 
neuroendocrine transformation was recently reported in a patient who developed acquired 
resistance to crizotinib (Caumont et al., 2016). Unlike that observed in EGFR inhibitor 
resistance, only ~one-third of patients with crizotinib resistance harbor an ALK mutation, 
and there are numerous mutations that can drive resistance. Two of the most commonly 
observed mutations are L1196M and G1269. Amino acid 1196 is considered the gatekeeper 
residue of ALK and, similar to EGFR, it controls access to the active site; therefore, the 
bulky substitution of methionine causes steric hindrance, impeding crizotinib binding (Choi 
et al., 2010). Individual mutations have been shown to confer variable degrees of crizotinib 
resistance (Heuckmann et al., 2011; Katayama et al., 2012). Activation of alternative 
signaling pathways, or bypass tracks, can occur via genomic or non-genomic mechanisms. 
These alterations lead to constitutive activation of redundant downstream pathways, 
rendering crizotinib incapable of suppressing tumor growth. Non-genomic mechanisms of 
resistance include increased phosphorylation of other tyrosine kinases (e.g., EGFR, IGF-1R, 
and Src); genomic alterations include mutations in EGFR, c-KIT, MAPK, and KRAS 
(Isozaki et al., 2015) (Fig. 3).
Multiple potential strategies exist to combat crizotinib resistance. The most well established 
second-line therapeutic option in patients who progress after receiving crizotinib is second-
generation ALK inhibitors. Ceritinib, an FDA-approved second-generation ALK inhibitor, is 
20-fold more potent against ALK than crizotinib and also inhibits IGF-1R (insulin-like 
growth factor 1 receptor). In a phase 1 clinical study, among the 80 patients who had 
received crizotinib previously, there was a 56% response rate to ceritinib in patients with 
various ALK resistance mutations (Shaw et al., 2014). A preclinical study suggests that 
some crizotinib-resistance mutations (F1174C and G1202R) may not be sensitive to ceritinib 
and, in fact, may be mechanisms of acquired resistance to ceritinib as well (Friboulet et al., 
2014). Alectinib, another second-generation ALK inhibitor with efficacy in patients who 
progressed on crizotinib received FDA-approval December 2015 (Shaw et al., 2016b). 
Interestingly, acquired mutations in ALK (I1171N and F1245C), have been reported to 
confer resistance to alectinib, but are susceptible to ceritinib (Kodityal et al., 2016; Ou et al., 
2015). Interestingly, acquired resistance to lorlatinib (via ALK L1198F), a third-generation 
ALK inhibitor in clinical trials, has been reported to enhance crizotinib binding and 
resensitize resistant tumors (Shaw et al., 2016a). Findings such as these may be important 
when considering sequencing of therapy in resistant patients.
Strategies to overcome crizotinib resistance due to bypass track signaling are less well 
studied. However, rational combination therapies have been postulated. For example, a 
preclinical study in ALK-positive NSCLC cell lines with acquired IGF-1R upregulation 
demonstrated improved efficacy of combined ALK (crizotinib) and IGF-1R inhibition 
(OSI-906) (Lovly et al., 2014). In the case of EGFR-mediated mechanism of acquired 
resistance, combination therapy with an ALK and EGFR inhibitor has been suggested to be 
effective (Katayama et al., 2012; Yamaguchi et al., 2014). Other plausible combinations 
include ALK inhibition concurrently with MEK or Src inhibitors. Heat shock protein 90 
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(HSP90) inhibitors have also demonstrated efficacy against ALK-sensitive and ALK-mutant 
NSCLCs (Katayama et al., 2012; Sang et al., 2013). HSP90 is a molecular chaperone that 
aids in proper folding of specific target proteins; ALK fusion proteins are substrates of 
HSP90. The combination of crizotinib plus HSP90 inhibitors is currently in clinical trials 
(NCT01712217).
Acquired resistance to BCR-ABL inhibitors in hematologic malignancies
Imatinib is an inhibitor of the BCR-ABL fusion gene, also referred to as the Philadelphia 
chromosome, that is characteristic of CML and presents at lower frequencies in ALL and 
acute myeloid leukemia (AML). BCR-ABL is a constitutively active tyrosine kinase that 
functions by binding ATP and transferring a phosphate group to tyrosine residues to activate 
downstream signaling molecules. Imatinib competitively binds to the kinase pocket of BCR-
ABL, inhibiting phosphorylation and downstream signaling (Savage and Antman, 2002; 
Signorovitch et al., 2014; Waller, 2014). The majority of CML patients will achieve 
clinically significant responses to imatinib. A complete and durable cytogenetic response is 
achieved in up to 80% of newly diagnosed patients and approximately 60% of patients with 
chronic-phase CML (Druker et al., 2006; Kantarjian et al., 2002). However, up to 27% of 
patients have been shown to develop resistance and relapse (Press et al., 2007).
Acquired resistance to imatinib occurs as a consequence of reactivation of BCR-ABL 
signaling, which can be due to BCR-ABL amplification, elimination of imatinib from the 
cell by multidrug efflux transporters, or, most commonly, by the development of BCR-ABL 
mutations (Gorre et al., 2001). The acquired mutations in BCR-ABL that have been 
associated with resistance to imatinib and other BCR-ABL inhibitors, such as nilotinib and 
dasatinib, are located in 12 key positions of ABL1 (Abelson murine leukemia viral 
oncogene, homolog 1). These result in amino acid substitutions that change the BCR-ABL 
binding site, altering the ability of the PKI to bind and inhibit downstream signaling 
(Zabriskie et al., 2014). The most commonly observed BCR-ABL mutation conferring 
acquired resistance is T315I, followed by E255K/V. Interestingly, multiple acquired 
mutations in BCR-ABL have been identified, and the degree of imatinib (and other BCR-
ABL PKI) resistance is dependent on the location of the point mutation within the BCR-
ABL binding site (Shah et al., 2002). Strategies to overcome acquired resistance to BCR-
ABL PKIs are currently being explored.
The second generation PKIs, such as nilotinib and dasatinib, were designed with a higher 
affinity for BCR-ABL in attempts to combat imatinib resistance. While they are able to 
overcome some mutations observed in acquired imatinib resistance, they are ineffective 
against the common T315I mutation (Zabriskie et al., 2014). In 2012, a third generation 
BCR-ABL PKI, ponatinib, was approved. Ponatinib is unique in that it is a high affinity pan-
BCR-ABL inhibitor with activity in T315I-positive CML. Despite its effectiveness against 
the acquired T315I mutation, emergence of compound mutations in BCR-ABL have been 
identified as conferring differential resistance to ponatinib (Zabriskie et al., 2014). Complex 
screening of resistance mutations and sensitivity to BCR-ABL PKIs is necessary to optimize 
therapy selection at the time of disease progression.
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Acquired resistance to BCR-ABL inhibitors in solid tumors
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the 
gastrointestinal tract, characterized by positive staining for KIT (the v-kit Hardy-Zuckerman 
4 feline sarcoma viral oncogene). Approximately 95% of GISTs express KIT, 80% have 
mutations in KIT, and 10% have mutations in the platelet-derived growth factor receptor 
alpha (PDGFRA) (Joensuu et al., 2013). Wild type GISTs lack KIT expression as well as 
KIT and PDGFRA mutations; alterations identified in wild type patients include mutations 
in BRAF, RAS, NF1, and succinate dehydrogenase deficiency. Imatinib is recommended 
first-line in GIST due to its inhibition of KIT and PDGFRA. Furthermore, KIT and 
PDGFRA mutations are associated with response to imatinib, with 84% of mutation-positive 
patients achieving a partial response compared to 0% of wild type patients (Heinrich et al., 
2003). Despite high initial response rates, approximately 80% of GIST patients will develop 
imatinib resistance within 12–36 months (Joensuu et al., 2013).
As observed in hematologic malignancies, acquired imatinib resistance in GIST is most 
commonly due to secondary alterations in the drug targets. However, because the oncogenic 
targets differ, so do the resistance alterations. A retrospective analysis of tumors from 
patients who progressed on the phase 2 B2222 imatinib trial indicated that 22 of 33 (67%) 
patients with acquired resistance had secondary mutations in KIT or PDGFRA (Heinrich et 
al., 2006). Interestingly, secondary KIT mutations were only observed in patients with 
primary KIT mutations, and the secondary PDGFRA mutation was identified in a patient 
with a primary PDGFRA mutation. The acquired mutations were all located within the ATP-
binding pocket of KIT (e.g., T670I, the gatekeeper mutation) or the activation loop, thus 
inhibiting imatinib binding and inactivation of KIT-mediated signaling.
Current treatment strategies for acquired resistance to imatinib in GIST focus on more 
potent inhibition of KIT and PDGFRA. Sunitinib, a multi-targeted PKI with activity against 
KIT, PDGFRA, VEGF, and numerous other tyrosine kinases, is currently approved second-
line in patients with imatinib-resistant disease. Sunitinib has activity against all resistant 
genotypes, but response rates are significantly higher in wild-type GIST (p= 0.04) and 
patients with mutations in the ATP-binding domain (p= 0.0005) when compared to patients 
with alterations in the activation loop (Heinrich et al., 2008). Efficacy of the third-line 
treatment, regorafenib, may be due to sufficient activity in patients with acquired alterations 
in the activation loop of KIT (George et al., 2012). Despite their increased specificity for 
resistant disease, phase 3 clinical trial response rates to sunitinib and regorafenib were only 
7% and 4.5%, and time to progression was 27 and 17 weeks, respectively (Demetri et al., 
2013; Demetri et al., 2006). These low response rates suggest that the majority of imatinib-
resistant GISTs may be entirely resistant to KIT inhibition, require more potent inhibitors, or 
may require alternative inhibition strategies.
Mutations and amplifications of KIT are also observed in melanomas (~3%), with higher 
frequencies in mucosal (39%), acral (36%), and chronically sun-damaged (28%) subtypes, 
suggesting possible benefit from imatinib (Curtin et al., 2006). A phase 2 trial of imatinib in 
patients with KIT-positive metastatic melanoma demonstrated potential efficacy, with 53.5% 
of the patients achieving a response and a 6-month PFS rate of 36.6% (Guo et al., 2011). 
Another phase 2 trial identified differential response rates between melanoma patients with 
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KIT mutations versus KIT amplification (54% vs. 0%, respectively) (Hodi et al., 2013). 
Retrospective data from patients with KIT-mutated melanoma demonstrated potential 
efficacy of sunitinib; of 4 evaluable patients, 3 (75%) responded to sunitinib (1 complete 
remission and 2 partial responses) (Minor et al., 2012). Additional studies support use of 
sunitinib in mucosal and acral subtypes of melanoma, but failed to show an association 
between KIT status and response (Buchbinder et al., 2015; Mahipal et al., 2012). Despite 
clinical benefit and relatively high initial response rates, most patients eventually progress 
on these therapies.
Similar to hematologic malignancies and GIST, the current strategy to overcome acquired 
resistance to KIT inhibition in melanoma is the use of more potent inhibitors. Nilotinib, the 
BCR-ABL PKI used in chemoresistant CML, also has activity against KIT, PDGFR, DDR, 
and several other protein kinases, with greater potency than imatinib. Recently, a phase 2 
study of niltonib demonstrated potential efficacy in patients with acquired resistance to prior 
KIT inhibitors. The primary endpoint, 4-month disease control, was achieved in 27% of 
resistant patients (95% CI 8% – 56%), and two partial responses (18.2%, CI 3% – 47%) 
were observed (Carvajal et al., 2015). A similar phase 2 study of nilotinib in KIT-positive 
melanomas in a Korean population failed to meet its primary endpoint of response rate 
(overall response rate was 16.7%). However, 6 of the 7 responses observed occurred in 
patients with KIT mutations only (24% response rate in KIT-mutated melanoma), 
suggesting that nilotinib may provide benefit in this subgroup (Lee et al., 2015b). As in 
GIST, KIT status seems to be a biomarker of response to imatinib in melanoma, but 
resistance inevitably develops. Current strategies to combat resistance are the same as GIST, 
with stronger inhibition of KIT, but response rates are low and not durable. Further 
understanding of the mechanisms of resistance and means to effectively suppress drivers of 
drug resistance are crucial to achieve durable responses in GIST and melanoma patients.
Acquired resistance to BRAF inhibition
BRAF, a serine/threonine kinase, plays a key role in the MAPK signaling pathway, which 
affects cell division, differentiation, and growth. Mutations in BRAF have been associated 
with numerous cancers, including CRC, melanoma, thyroid carcinoma, NSCLC, and non-
Hodgkin’s lymphoma. Most commonly observed are somatic mutations causing activation 
of BRAF, specifically a valine to glutamine or lysine substation at position 600 (V600E/K), 
and constitutive signaling through the MAPK pathway. The discovery of BRAF mutations in 
cancer led to development of drugs aimed at inhibiting this oncogenic driver. In 2011, the 
first selective BRAF inhibitor, vemurafenib, was FDA-approved for the first-line treatment 
of BRAF V600E-positive melanoma after interim review of a phase 3 randomized controlled 
trial that demonstrated improved OS (84% vs. 64%) and PFS (5.3 months vs. 1.6 months) 
(Chapman et al., 2011). Debrafenib, a second BRAF inhibitor, demonstrated similar efficacy 
(PFS 5.1 vs. 2.7 months, HR 0.30, p<0.0001) and, was approved for the treatment of BRAF-
positive melanoma in 2013 (Hauschild et al., 2012). It was realized early that, despite high 
initial levels of response, efficacy of BRAF inhibitors alone is not durable, with most 
patients developing resistance within 6–8 months (McArthur et al., 2014).
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Most mechanisms of acquired resistance to BRAF inhibitors involve reactivation of the 
MAPK pathway; unlike EGFR and ALK, no secondary or gatekeeper-type mutations have 
been identified as resistance drivers (Nazarian et al., 2010). Secondary resistance may be 
driven upstream (e.g., upregulation and activation of the other receptor tyrosine kinases), 
downstream (e.g., activating MEK1/2 mutations), at the level of BRAF (e.g., alternative 
splicing, BRAF V600E amplification), or elevated CRAF levels. Observed genetic 
alterations in the setting of acquired resistance include mutations that activate NRAS, 
MEK1, and MEK2 (Emery et al., 2009; Nazarian et al., 2010; Van Allen et al., 2014). 
Amplification of mitogen-activated protein kinase kinase kinase 8 (MAP3K8 or COT) is 
another mechanism of resistance, which results in RAF-independent activation of MEK and 
ERK signaling (Johannessen et al., 2010).
One potential strategy to circumvent or delay BRAF inhibitor resistance is dual inhibition of 
components of the MAPK-pathway. In a phase 3 clinical trial of BRAF and MEK inhibition 
vs. BRAF inhibition alone in melanoma, the combination of dabrafenib plus trametinib 
improved PFS when compared to debrafenib alone (9.3 vs. 8.8 months, HR 0.75, p= 0.03); 
significant improvements in response rates and OS were also observed (Long et al., 2014). 
Trametinib is now FDA approved as monotherapy or in combination with dabrafenib. 
Interestingly, the benefit of MEK inhibitors was not observed when administered as 
monotherapy in patients who had progressed after initial benefit from a BRAF inhibitor, 
suggesting that MEK inhibition alone is not sufficient to overcome BRAF resistance (Kim et 
al., 2013). Preclinical data suggests another potential strategy to delay or overcome 
resistance caused by increased MAPK signaling is concurrent or sequential inhibition of 
BRAF and ERK (Hatzivassiliou et al., 2012; Herrero et al., 2015; Wong et al., 2014). 
However, while dual inhibition of the MAPK pathway has shown benefit, acquired 
resistance occurs within 12 months. Known mechanisms of acquired resistance to BRAF 
plus MEK inhibition are similar to those observed with BRAF inhibitor monotherapy, and 
include amplification of BRAF V600, which activates CRAF and subsequently MAPK 
signaling, and acquired MEK1/2 mutations (Moriceau et al., 2015; Villanueva et al., 2013; 
Wagle et al., 2014). Preclinical studies investigating even broader combination therapy 
consisting of concurrent BRAF, MEK, and PI3K/mTOR inhibition have demonstrated 
potential efficacy in BRAF/MEK-induced resistance (Carlino et al., 2014; Moriceau et al., 
2015; Villanueva et al., 2013). In addition, like ALK, BRAF V600E is a client of HSP90, 
and preclinical studies suggest that treatment with an HSP inhibitor may be another 
successful strategy to overcome BRAF and MEK inhibitor resistance (Smyth et al., 2014).
MAPK-independent mechanisms of acquired resistance to BRAF inhibition have also been 
identified, and dual inhibition has been proposed as a strategy to overcome this resistance. 
The most well studied bypass track of BRAF inhibitor resistance is activation through the 
PI3K/Akt signaling pathway. For example, increased expression of PDGFRB or IGF-1R has 
been observed in cell culture and patient xenograft models of secondary resistance. Over-
activation of these receptors results in activation of alternate signaling pathways (e.g., PI3K/
Akt), which can reduce the cancer cells’ dependency on MAPK signaling, rendering the 
cells resistant to BRAF-mediated inhibition (Nazarian et al., 2010; Villanueva et al., 2010). 
Secondary mutations in PI3K pathway regulatory genes, such as AKT1/3, PIK3CA, 
PIK3CG, PIK3R2, and PTEN have also been observed, further supporting combination 
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therapy with PI3K inhibitors (Shi et al., 2014a). Preclinical data demonstrated efficacy of 
concurrent PI3K and MEK inhibition in BRAF resistant cell lines, and clinical trials of this 
combination are currently underway (NCT01363232, NCT01337765). Recently, expression 
of yes-associated protein 1 (YAP1), a member of the Hippo signaling pathway, was 
associated with resistance to BRAF and MEK inhibition, and preclinical studies 
demonstrated that triple therapy with a BRAF, MEK, and YAP inhibitor may be a promising 
strategy to increase response in the setting of resistance (Lin et al., 2015).
Conclusions
Targeted therapies are increasingly common and recommended first-line in some cancer 
types due to their impressive increases in response rates and survival benefits when 
compared to standard cytotoxic chemotherapy. However, even in the presence of a genetic 
biomarker predictive of response, not all patients will benefit from such therapies (intrinsic 
resistance), and for those who do, durable response rates are low (acquired resistance). 
Therefore, equally important as identifying targetable oncogenic alterations is the 
identification of biomarkers of intrinsic resistance and the ability to anticipate potential 
mechanisms of acquired resistance that may develop.
As discussed in this article, the most common mechanisms of acquired resistance to targeted 
therapies induce upregulation of the drug target or bypass signaling through the same or 
similar pathways, resulting in cancer progression. These patterns imply an evolutionary-like 
process in which the cells most fit to regulate cellular proliferation and survival are selected. 
The question of whether or not resistant cells are present at undetectable concentrations at 
diagnosis or whether they develop post-treatment remains unanswered. Specifically, does 
resistance arise from pre-existing clones or is there drug-induced selection pressure that 
drives acquisition of mutations? It is likely that both may be the case.
An important concept in the context of resistance to anticancer therapies is that a biomarker 
conferring response or resistance in one tumor type may or may not be predictive in all 
tumor types. For example, approximately 10% of CRCs carry BRAF V600 mutations, but 
are resistant to BRAF inhibition (Corcoran et al., 2015; Kopetz et al., 2015). However, in a 
recent “basket” study of vemurafenib in BRAF V600-mutated non-melanoma cancers (n = 7 
tumor classifications, including CRC), patients with NSCLC and Erdheim-Chester disease 
or Langerhans’-cell histiocytosis met the predetermined overall response rate of >35%, 
suggesting that BRAF status may be important in those tumor types (Hyman et al., 2015). 
Recently, vemurafenib also demonstrated efficacy in BRAF-positive hairy cell leukemia 
(Tiacci et al., 2015). Another example is RAS-status as a predictor of intrinsic resistance to 
EGFR monoclonal antibodies in CRC, but not predictive of response to EGFR inhibition in 
NSCLC. Interestingly, secondary mutations in EGFR have been reported as mechanisms of 
acquired resistance in both tumor types.
Lack of efficacy across tumor types may be reflective of differential oncogenic drivers or 
compensatory resistance mechanisms. In CRC, data suggests that BRAF inhibition is 
overcome through increased EGFR-mediated signaling; this bypass track is not clinically 
relevant in melanoma due to low basal levels of EGFR in this cancer type (Corcoran et al., 
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2012). Therefore, dual BRAF and EGFR inhibition may be required to increase response 
rates in BRAF-mutant CRC (Atreya et al., 2015; Napolitano et al., 2015). The benefit of 
imatinib in hematologic malignancies with BCR-ABL translocations and solid tumors with 
KIT or PDGFRA mutations is a unique example of how different oncogenic drivers may 
respond to the same therapy, but result in different genetic mechanisms of acquired 
resistance.
Future directions
Treatment modalities to prevent and overcome drug resistance are critical to increase the rate 
of durable responses to cancer therapies (Fig. 4). To date, most strategies used in clinical 
practice involve sequential dosing once resistance develops (Fig. 4A). An alternative strategy 
is to predict and target known resistance pathways from the outset using combination 
therapy (Fig. 4B). The strength of this approach is supported by the increased benefit of 
dabrafenib plus trametinib vs. dabrafenib alone in BRAF-mutated melanoma (Long et al., 
2015). However, while this prolongs duration of response, resistance inevitably develops. 
Studies indicate development of BRAF inhibitor dependence in melanoma cells, which may 
also be combatted with intermittent or continuous dosing (Das Thakur et al., 2013; Dooley 
et al., 2014) (Fig. 4C). Another possible strategy is pulse dosing, in which the targeted 
therapy is administered for a short time (maybe until progression), stopped temporarily, and 
then restarted (Fig. 4D). This method is supported by serial biopsies of EGFR-positive 
NSCLC resistance which demonstrated that patients may re-develop the T790M mutation 
after withdrawal and, therefore, respond to reinitiation of an EGFR inhibitor (Sequist et al., 
2011). Finally, some patients with advanced disease may benefit from immunotherapy, but 
identification of this subset is much less understood.
Despite overall response rates of 50% to 80% in clinical trials of targeted anticancer 
therapies, mechanisms of intrinsic resistance have yet to be fully elucidated. Intrinsic 
resistance may be attributed to germline genetics (e.g., BIM or TPMT) or somatic alterations 
(e.g., KRAS in CRC). Drug metabolism and germline variants that may affect exposure to 
cancer therapies are also an important consideration in the context of intrinsic resistance 
[reviewed in (Hertz and Rae, 2015; Kathawala et al., 2015)]. However, robust examples of 
intrinsic resistance to targeted anti-cancer therapies are lacking. Furthermore, mechanisms of 
resistance to PKIs that inhibit multiple targets, such as sorafenib and sunitinib, are even 
more challenging to elucidate due to the heterogeneity of their effects, and are even less 
studied. Another interesting gap in the area of resistance to anticancer therapies involves 
potential racial disparities. Certain alterations are known to be more common in some races 
(e.g., EFGR mutations in Asian populations), suggesting potential differences in racial 
trends of oncogenic drivers. Because clinical and genetic studies enroll a vast majority of 
Caucasian patients, these potential disparities in genetic oncogenesis between races, which 
can greatly affect response rates, have yet to be elucidated.
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Figure 1. Mechanisms of oncology drug resistance
(A) Pharmacological resistance. Drug-drug interactions and germline pharmacogenetic 
variants can affect drug exposure at the tumor site. Pharmacological properties can affect 
drug penetration into the central nervous system. (B) Biological resistance. Somatic 
(acquired) mutations in the drug target can affect the drug’s ability to effectively inhibit 
oncogenesis. Somatic alterations downstream of the drug target can result in constitutive 
upregulation of oncogenic pathways. Genetic alterations may also activate alternative 
oncogenic signaling pathways. Some tumor types have been shown to transform into other 
tumor types (e.g., non-small cell lung cancer to small cell lung cancer). (C) Pharmacological 
drug resistance results from inadequate drug levels at the site of action, whereas biological 
drug resistance results despite adequate drug levels at the site of action. (D) Intrinsic 
resistance is the lack of even transitory clinical benefit – the tumor continues to progress 
despite treatment. (E) Acquired resistance is the lack of tumor response to medication 
despite initial benefit.
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Figure 2. Example mechanisms of resistance to EGFR inhibitors and potential treatment 
strategies: The MAPK and PI3K/AKT pathways
EGFR-mutated non-small cell lung cancers show initial response to EGFR inhibitors (e.g., 
erlotinib, gefetinib). Mechanisms of acquired resistance include secondary EGFR mutations, 
downstream mutations that result in EGFR-independent activation of MAPK or PI3K/AKT 
signaling pathways, or mutations in alternative protein kinases that bypass EGFR-mediated 
signaling through MAPK and/or PI3K/AKT pathways. Potential treatment strategies to 
combat acquired resistance to EGFR inhibitors include stronger inhibiton of EGFR (e.g., 
afatinib), combination therapy with a MEK (e.g., trametinib) or mTOR (e.g., sirolimus) 
inhibitor, or inhibition of bypass tracks.
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Figure 3. Mechanisms of acquired resistance to protein kinase inhibitors
(A) and (B) data from Camdige et al., 2014. (C) Data from Shi et al., 2013. The all-blue pie 
chart represents MAPK-mediated mechanisms of resistance. PI3K/AKT-mediated 
mechanisms include AKT1/3 mutations (3%), mutations in positive-regulatory genes, 
PIK3CA and PIK3CG, and mutations in negative-regulatory genes PIK3RS, PTEN, and 
PHLPP1.
Blue shades throughout correspond to alterations within the targeted oncogenic track; orange 
shades correspond to alterations regulating alternative or bypass tracks; yellow shades 
correspond to phenotypic transformations. NSCLC: non-small cell lung cancer, SCLC: small 
cell lung cancer, EMT: epithelial to mesenchymal subtype.
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Figure 4. Potential treatment strategies to combat anticancer drug resistance
(A) Sequential dosing. Begin treatment with single targeted therapy, once resistance 
develops, switch to drug that targets resistant cells. (B) Combination therapy. Begin therapy 
with a medication that targets the identified oncogenic marker in combination with a drug 
targeting predicted resistance mechanisms. (C) Continuous therapy. Begin treatment with a 
single targeted therapy, once resistance develops, add medication that targets resistance 
mechanism. (D) Pulse dosing. Begin treatment with single targeted therapy and periodically 
administer medication that targets predicted resistance mechanism. (A) represents the most 
commonly used strategy to date. Some data suggest that (B), (C), and/or (D) may delay 
development of acquired resistance.
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